ArticleDiscover oncology2026

Bevacizumab added to conventional induction chemotherapy for children with high risk neuroblastoma (BRAVEN trial).

Jagdish Prasad Meena et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.